{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:54:47Z","timestamp":1649195687227},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med","J. Jpn. Soc. Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/naika.103.717","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T22:07:29Z","timestamp":1425938849000},"page":"717-723","source":"Crossref","is-referenced-by-count":0,"title":["7. Progress in Treatment for Hematologic Diseases"],"prefix":"10.2169","volume":"103","author":[{"given":"Masaaki","family":"Higashihara","sequence":"first","affiliation":[{"name":"Department of Hematology, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1) McKenna RW, et al: Plasma cell neoplasms. Swerdlow SH, et al, eds. WHO classifications of the tumours of haematopoietic and lymphoid tissues, IARC Press, 2008, 200-213."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hochhaus A: Therapy of newly diagnosed and chronic-phase chronic myeloid leukemia. Faderl S, Kantarjian H, eds. Leukemias, Wiley-Blackwell, 2011, 271-286.","DOI":"10.1002\/9781444327359.ch22"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3) Kantarjian HM, et al: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119: 1123-1129, 2012.","DOI":"10.1182\/blood-2011-08-376087"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Fenaux P, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223-232, 2009.","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Rose C, et al: Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des My\u00e9lodysplasies). Leuk Res 34: 864-870, 2010.","DOI":"10.1016\/j.leukres.2009.12.004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Lymphoma Study Group of Japanese Pathologists: The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Pathol Int 50: 696-702, 2000.","DOI":"10.1046\/j.1440-1827.2000.01108.x"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Coiffier B, et al: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116: 2040-2045, 2010.","DOI":"10.1182\/blood-2010-03-276246"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Watanabe M, et al: Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection. Liver Int 31: 340-347, 2011.","DOI":"10.1111\/j.1478-3231.2010.02417.x"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9) Rummel MJ, et al: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381: 1203-1210, 2013.","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Yamada Y, et al: A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113: 375-382, 2001.","DOI":"10.1046\/j.1365-2141.2001.02737.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Tobinai K, et al: Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep 7: 235-240, 2012.","DOI":"10.1007\/s11899-012-0124-3"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12) Kumar SK, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520, 2008.","DOI":"10.1182\/blood-2007-10-116129"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14) Moreau P, et al: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12: 431-440, 2011.","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"14","doi-asserted-by":"publisher","unstructured":"15) Durie BG, et al: International uniform response criteria for multiple myeloma. Leukemia 20: 1467-1473, 2006.","DOI":"10.1038\/sj.leu.2404284"},{"key":"15","doi-asserted-by":"publisher","unstructured":"16) Saleh MN, et al: Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 121: 537-545, 2013.","DOI":"10.1182\/blood-2012-04-425512"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17) Shirasugi Y, et al: An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Int J Hematol 95: 652-659, 2012.","DOI":"10.1007\/s12185-012-1065-2"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.53.433"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19) Saito H, et al: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5: 31-41, 2007.","DOI":"10.1111\/j.1538-7836.2006.02267.x"},{"key":"19","doi-asserted-by":"publisher","unstructured":"20) Nishimoto N, et al: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959-3964, 2008.","DOI":"10.1182\/blood-2008-05-155846"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21) Rother RP, et al: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25: 1256-1264, 2007.","DOI":"10.1038\/nbt1344"},{"key":"21","doi-asserted-by":"publisher","unstructured":"22) Parker C: Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373: 759-767, 2009.","DOI":"10.1016\/S0140-6736(09)60001-5"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":["7\uff0e\u8840\u6db2\u5185\u79d1\u9818\u57df\u306e\u6cbb\u7642\u306e\u9032\u6b69"],"language":"en","deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T20:21:00Z","timestamp":1566418860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/103\/3\/103_717\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.103.717","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}